Free Research Report Download:
The Cancer Market Outlook To 2014
Free Pharmaceutical Market Research Reports
Biotechnology
Corporate & Fiscal
Drug Delivery
Health Products
Hospital Markets
Indication Areas
Medical Devices
Prescription Medicines
R&D
Custom Research
Pharmaceutical Events & Conferences
Contact
Terms & Conditions
Privacy
Home >
World Smoking-Cessation Drug Market 2010-2025
Market Study
Published: January 2010
Pages: 123
Tables: For full details, please email keithw@cmsinfo.com
From: GBP 1499.00 Buy Now!
Research from: pharmaceuticalmarketresearch
Sector: Prescription Medicines
– how will this important anti-addiction market develop? Our new report explains
Smoking is a leading cause of preventable death worldwide. In 2009, total sales of smoking-cessation products surpassed $1.6bn (Rx products). The effects of smoking constitute a major burden on public healthcare systems, as well as lowering quality of life for many people. Currently-marketed smoking-cessation products arguably lack the desired levels of efficacy in practice, with the reputation of some suffering through noted side-effects. As a result, there are significant commercial opportunities for more-efficacious and better-tolerated smoking-cessation agents, especially in prescription form.
Our new report – World Smoking-Cessation Drug Market 2010-2025 – forecasts how the anti-smoking drug market will develop over the next 15 years. We predict that the launch of new smoking-cessation aids early this decade will answer some unmet needs currently limiting that pharma market segment. Besides extensive coverage of currently-marketed drugs, this report examines the most exciting products currently in development. We also include external opinions on the sector, gained thorough original unique surveys.
Our report analyses current leading markets in North America, Europe and Asia in detail. A major contribution to the market during the next 15 years will come from emerging economies, led by India and China. Almost half of the world’s smokers live in those countries, with almost a third in China alone, reports suggest. At present, those national markets yield relatively low smoking-cessation revenues. However, visiongain predicts that the emerging economies have a large potential for sales growth of smoking-cessation products. This report reveals how their sales revenues and market shares will expand during the forecast period.
The majority of smokers worldwide do not have full access to smoking-cessation therapies at present. The high economic and social costs associated with tobacco use are driving anti-smoking legislation and encouraging governmental spending on tobacco-dependency treatments. From 2010 to 2025, the implementation and expansion of tobacco-control policies – especially public smoking bans – will continue. Combined, those policies will help to increase the use of smoking-cessation products, agents still with a long way to go in their technological and commercial development, our report shows.
Comprehensive analysis of the smoking-cessation pharmaceutical market
World Smoking-Cessation Drug Market 2010-2025 critically examines that sector through a comprehensive review of primary and secondary information sources. Our new report provides detailed sales forecasts, market share analyses, discussions of pipeline developments and analyses of commercial drivers and restraints. There are over 50 tables and figures included, as well as two interviews with relevant experts. The result is a comprehensive market- and industry-centred study, with detailed analyses and informed opinion to benefit your work.
Highlights of the report include:
• Sales forecasts for the smoking-cessation drug market, leading therapy types and top products at global level
• Detailed examination of the smoking-cessation markets in the US, Canada, the UK, France, Germany, Sweden, Denmark, Japan, China and India, with sales forecasts
• Examination of strengths, weakness, opportunities and threats (SWOT factors) facing the industry and market
• Analysis of the R&D pipeline for smoking-cessation products.
Why you should buy World Smoking-Cessation Drug Market 2010-2025
This report gives you the following benefits in particular:
• You will receive a comprehensive analysis of the prospects for smoking-cessation drugs from 2010 to 2025, including predicted revenues, growth rates and other key metrics
• You will find out where the market is heading - both technologically and commercially - from the present onwards, both for the overall world market and for leading national markets
• You will discover prospects for Chantix/Champix, in light of recent concerns
• You will identify key pipeline developments and up-and-coming products
• You will discover the drivers, restraints, competition and opportunities influencing the smoking-cessation market, including those for nicotine replacement therapies, Pfizer’s Chantix/Champix and bupropion drugs
• You will receive expert views from our original unique interviews - unavailable anywhere else
Our research shows that new smoking-cessation drugs should achieve commercial success if they are clearly tolerable and more effective in practice than existing products, easily accessible, backed by innovative marketing campaigns and delivered in combination with behavioural support programmes. Smoking-cessation drugs with those characteristics would have good overall prospects with regulators and healthcare providers.
You can obtain this report today
Nobody with an interest in the smoking-cessation market should overlook this new study. We predict that total revenues will increase over our forecast period, 2010 to 2025. With rising demand for products worldwide and currently-unmet needs, this therapeutic area holds significant potential for further revenue growth and technological innovation. Do you want to harness those opportunities? You can stay ahead by ordering this report today.
Smoking is a leading cause of preventable death worldwide. In 2009, total sales of smoking-cessation products surpassed $1.6bn (Rx products). The effects of smoking constitute a major burden on public healthcare systems, as well as lowering quality of life for many people. Currently-marketed smoking-cessation products arguably lack the desired levels of efficacy in practice, with the reputation of some suffering through noted side-effects. As a result, there are significant commercial opportunities for more-efficacious and better-tolerated smoking-cessation agents, especially in prescription form.
Our new report – World Smoking-Cessation Drug Market 2010-2025 – forecasts how the anti-smoking drug market will develop over the next 15 years. We predict that the launch of new smoking-cessation aids early this decade will answer some unmet needs currently limiting that pharma market segment. Besides extensive coverage of currently-marketed drugs, this report examines the most exciting products currently in development. We also include external opinions on the sector, gained thorough original unique surveys.
Our report analyses current leading markets in North America, Europe and Asia in detail. A major contribution to the market during the next 15 years will come from emerging economies, led by India and China. Almost half of the world’s smokers live in those countries, with almost a third in China alone, reports suggest. At present, those national markets yield relatively low smoking-cessation revenues. However, visiongain predicts that the emerging economies have a large potential for sales growth of smoking-cessation products. This report reveals how their sales revenues and market shares will expand during the forecast period.
The majority of smokers worldwide do not have full access to smoking-cessation therapies at present. The high economic and social costs associated with tobacco use are driving anti-smoking legislation and encouraging governmental spending on tobacco-dependency treatments. From 2010 to 2025, the implementation and expansion of tobacco-control policies – especially public smoking bans – will continue. Combined, those policies will help to increase the use of smoking-cessation products, agents still with a long way to go in their technological and commercial development, our report shows.
Comprehensive analysis of the smoking-cessation pharmaceutical market
World Smoking-Cessation Drug Market 2010-2025 critically examines that sector through a comprehensive review of primary and secondary information sources. Our new report provides detailed sales forecasts, market share analyses, discussions of pipeline developments and analyses of commercial drivers and restraints. There are over 50 tables and figures included, as well as two interviews with relevant experts. The result is a comprehensive market- and industry-centred study, with detailed analyses and informed opinion to benefit your work.
Highlights of the report include:
• Sales forecasts for the smoking-cessation drug market, leading therapy types and top products at global level
• Detailed examination of the smoking-cessation markets in the US, Canada, the UK, France, Germany, Sweden, Denmark, Japan, China and India, with sales forecasts
• Examination of strengths, weakness, opportunities and threats (SWOT factors) facing the industry and market
• Analysis of the R&D pipeline for smoking-cessation products.
Why you should buy World Smoking-Cessation Drug Market 2010-2025
This report gives you the following benefits in particular:
• You will receive a comprehensive analysis of the prospects for smoking-cessation drugs from 2010 to 2025, including predicted revenues, growth rates and other key metrics
• You will find out where the market is heading - both technologically and commercially - from the present onwards, both for the overall world market and for leading national markets
• You will discover prospects for Chantix/Champix, in light of recent concerns
• You will identify key pipeline developments and up-and-coming products
• You will discover the drivers, restraints, competition and opportunities influencing the smoking-cessation market, including those for nicotine replacement therapies, Pfizer’s Chantix/Champix and bupropion drugs
• You will receive expert views from our original unique interviews - unavailable anywhere else
Our research shows that new smoking-cessation drugs should achieve commercial success if they are clearly tolerable and more effective in practice than existing products, easily accessible, backed by innovative marketing campaigns and delivered in combination with behavioural support programmes. Smoking-cessation drugs with those characteristics would have good overall prospects with regulators and healthcare providers.
You can obtain this report today
Nobody with an interest in the smoking-cessation market should overlook this new study. We predict that total revenues will increase over our forecast period, 2010 to 2025. With rising demand for products worldwide and currently-unmet needs, this therapeutic area holds significant potential for further revenue growth and technological innovation. Do you want to harness those opportunities? You can stay ahead by ordering this report today.
Companies Listed
Action on Smoking on Health (ASH) [UK]
American Heart Association (AHA) [US]
American Lung Association (ALA) [US]
Biotie Therapies [Finland]
Biovail
Boehringer Ingelheim
Ceejay Healthcare
Celtic Pharma
Centers for Disease Control and Prevention (CDC) [US]
Cytos Biotechnology
European Medicines Agency (EMEA)
Evotec
Food and Drug Administration (FDA) [US]
Georgetown University School of Medicine [US]
GlaxoSmithKline (GSK)
Greater Rochester Tobacco Research Center
Independent Pharmaceutica
Johnson & Johnson
Karolinska Institutet [Sweden]
Lundbeck
Mayo Clinic [US]
Medical College of Wisconsin Research Foundation [US]
Medicines and Healthcare products Regulatory Agency (MHRA) [UK]
Ministry of Health, Labour and Welfare (MHLW) [Japan]
Mylan
Nabi Biopharmaceuticals
National Cancer Institute (NCI) [US]
National Health Service (NHS) [UK]
National Institute for Health and Clinical Excellence (NICE) [UK]
National Institute of Drug Abuse (NIDA) [US]
National Institutes of Health (NIH) [US]
Novartis
Perrigo
Pfizer
Pierre Fabre
Ruyan
Sanofi-Aventis
Sigma
The Smoking Research Program [US]
Somaxon
Sopharma
Taisho
Takeda
Targacept
Teva
University of California [US]
Watson
World Health Organization (WHO)
Zenara